Toggle light / dark theme

Facebook has built a tool called Getafix that automatically finds fixes for bugs and offers them to engineers to approve. This allows engineers to work more effectively, and it promotes better overall code quality. We believe Getafix is the first tool of its kind to be deployed to production at Facebook scale, contributing to the …

A system for transmission of information using a curl-free magnetic vector potential radiation field. The system includes current-carrying apparatus for generating a predominantly curl-free magnetic vector potential field coupled to apparatus for modulating the current applied to the field generating apparatus. Receiving apparatus includes a detector with observable properties that vary with the application of an applied curl-free magnetic vector potential field. Analyzing apparatus for determining the information content of modulation imposed on the curl-free vector potential field is coupled to the detector. The magnetic vector potential field can be established in materials that are not capable of transmitting more common electromagnetic radiation.

The receiver may detect changes of phase of the sine function which determines the Josephson junction current. The distance of the transmitter can be determined from the strength of the received signal. By generating a field of predetermined orientation and using a detector responsive to orientation, the direction of the transmitter may be determined. A rotating field may be used for this.

A Cambridge-based biotech company that is creating a colony of “human” mice is locked in a Tom and Jerry-style fight with a US pharmaceutical giant.

Kymab, which is backed by the Bill and Melinda Gates Foundation and counts fund manager Neil Woodford among its investors, is seeking permission to appeal to the Supreme Court in a row over patents. It follows a ruling by the Court of Appeal earlier this year that Kymab infringed a patent belonging to US company Regeneron. A previous judgment ruled that Regeneron’s patent was insufficient.

The legal tussle relates to Kymab’s “Kymouse” work, in which it manipulates the genome of mice. Kymab removes the genes that make antibodies in mice and replaces them with human antibody genes. This means that.

Global shipping has dropped off, and exporters are warning that refrigerated container (reefer) shortages pose major problems for food trade. Soil is even wetter than last year in US Midwest, presaging a difficult — and potentially catastrophic — 2020 season. UK is under water. China is shutdown. Australia reported record low crops. Grow food. Store it. Prepare for a limited collapse of our food system.

FULL SHOW NOTES:

SUPPORT THE SHOW:
http://patreon.com/iceagefarmer
http://paypal.me/iceagefarmer

JOIN THE CONVERSATION:

When tested in mice, the molecule, dubbed halicin, effectively treated the gastrointestinal bug Clostridium difficile (C. diff), a common killer of hospitalized patients, and another type of drug-resistant bacteria that often causes infections in the blood, urinary tract, and lungs.

The most surprising feature of the molecule? It is structurally distinct from existing antibiotics, the researchers said. It was found in a drug-repurposing database where it was initially identified as a possible treatment for diabetes, a feat that showcases the power of machine learning to support discovery efforts.